12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Influence of different rehabilitative aerobic exercise programs on (anti-) inflammatory immune signalling, cognitive and functional capacity in persons with MS – study protocol of a randomized controlled trial

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Studies have shown positive effects of therapeutic exercise on motor- and cognitive function as well as on psychosocial outcomes in persons with multiple sclerosis (MS). A reduction of inflammatory stress through physical exercise has been suspected as one key mechanism, mediating the positive effects of exercise in the context of MS. The primary objective of this trial is to investigate the acute and chronic effects of different exercise modalities on (anti-)inflammatory immune signalling as well as on cognitive and functional capacity in persons with MS.

          Methods

          A two armed single-blind randomized controlled design will investigate 72 persons with relapsing remitting or secondary progressive MS (EDSS 3.0–6.0), during 3 weeks of inpatient rehabilitation. Participants will be randomized into either a high-intensity interval training (HIIT) or a moderate continuous training group; the latter represents the local standard therapy (ST). Both groups will exercise 3x per week. The HIIT group will perform 5 × 1.5-min high-intensive exercise bouts at 95–100% of their maximum heart rate (HR max) followed by active breaks of unloaded pedalling (60% HR max) for 2 min. In contrast, the ST group will exercise for 24 min continuously at 65% of HR max. The proportion of circulating regulatory T-cells will be measured as primary outcome. Secondary outcomes comprise numbers and proportions of further immune cells including Th17-cells, soluble factors ((anti-) inflammatory cytokines, tryptophan metabolites), endurance capacity, cognitive performance, processing skills for activities of daily living, fatigue, depression and healthcare-related quality of life. Outcomes will be assessed before (T 0) and after (T 3) the 3-week exercise intervention program. Blood samples of T 0 will be taken immediately before the first exercise session. Additionally, blood samples for the soluble factors will be collected immediately after (T 1) and three hours (T 2) after the first exercise session of each group.

          Discussion

          This study will be the first to investigate both acute and chronic effects of aerobic exercise on immune function and disease associated biomarkers in persons with MS. Combining biological analyses with cognitive and functional capacity assessments may contribute to a better understanding of responses to rehabilitative training, needed to improve exercise recommendations for persons with MS.

          Trial registration

          This trial was prospectively registered at ClinicalTrials.gov ( NCT03652519; 29 August 2018).

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression.

          Depression is a debilitating condition with a profound impact on quality of life for millions of people worldwide. Physical exercise is used as a treatment strategy for many patients, but the mechanisms that underlie its beneficial effects remain unknown. Here, we describe a mechanism by which skeletal muscle PGC-1α1 induced by exercise training changes kynurenine metabolism and protects from stress-induced depression. Activation of the PGC-1α1-PPARα/δ pathway increases skeletal muscle expression of kynurenine aminotransferases, thus enhancing the conversion of kynurenine into kynurenic acid, a metabolite unable to cross the blood-brain barrier. Reducing plasma kynurenine protects the brain from stress-induced changes associated with depression and renders skeletal muscle-specific PGC-1α1 transgenic mice resistant to depression induced by chronic mild stress or direct kynurenine administration. This study opens therapeutic avenues for the treatment of depression by targeting the PGC-1α1-PPAR axis in skeletal muscle, without the need to cross the blood-brain barrier. Copyright © 2014 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

            Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures. Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use. Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients. Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if a further 10 minutes could be allocated for testing. Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A simple sample size formula for analysis of covariance in randomized clinical trials.

              Randomized clinical trials that compare two treatments on a continuous outcome can be analyzed using analysis of covariance (ANCOVA) or a t-test approach. We present a method for the sample size calculation when ANCOVA is used. We derived an approximate sample size formula. Simulations were used to verify the accuracy of the formula and to improve the approximation for small trials. The sample size calculations are illustrated in a clinical trial in rheumatoid arthritis. If the correlation between the outcome measured at baseline and at follow-up is rho, ANCOVA comparing groups of (1-rho(2))n subjects has the same power as t-test comparing groups of n subjects. When on the same data, ANCOVA is used instead of t-test, the precision of the treatment estimate is increased, and the length of the confidence interval is reduced by a factor 1-rho(2). ANCOVA may considerably reduce the number of patients required for a trial.
                Bookmark

                Author and article information

                Contributors
                n.joisten@dshs-koeln.de
                arademacher93@gmail.com
                w.bloch@dshs-koeln.de
                a.schenk@dshs-koeln.de
                m.oberste@dshs-koeln.de
                dalgas@sport.au.dk
                d.langdon@rhul.ac.uk
                daniel.caminada@risch.ch
                mette.purde@gmail.com
                roman.gonzenbach@kliniken-valens.ch
                jan.kool@kliniken-valens.ch
                +49 (0) 221 4982 5440 , p.zimmer@dshs-koeln.de
                jens.bansi@kliniken-valens.ch
                Journal
                BMC Neurol
                BMC Neurol
                BMC Neurology
                BioMed Central (London )
                1471-2377
                8 March 2019
                8 March 2019
                2019
                : 19
                : 37
                Affiliations
                [1 ]ISNI 0000 0001 2244 5164, GRID grid.27593.3a, Department of Molecular and Cellular Sport Medicine, , Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, ; Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
                [2 ]Deparment of Neurology, Kliniken-Valens, Rehabilitationsklinik-Valens, Taminaplatz 1, 7317 Valens, Switzerland
                [3 ]ISNI 0000 0001 1956 2722, GRID grid.7048.b, Department of Public Health, Section of Sport Science, , Århus University, ; Dalgas Avenue 4, 8000 Århus C, Denmark
                [4 ]ISNI 0000 0001 2188 881X, GRID grid.4970.a, Royal Holloway University of London, ; Egham, TW20 0EX Surrey UK
                [5 ]labormedizinisches zentrum Dr Risch, Lagerstrasse 30, 9470 Buchs, Switzerland
                [6 ]ISNI 0000 0004 0492 0584, GRID grid.7497.d, Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), ; Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
                Article
                1267
                10.1186/s12883-019-1267-9
                6407211
                30849952
                4ac56629-bd21-4ce2-a1bb-862d3b0870ce
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 27 November 2018
                : 4 March 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100008486, Schweizerische Multiple Sklerose Gesellschaft;
                Funded by: Stiftung für Ergotherapie
                Funded by: Grenzen überschreiten
                Funded by: Blumenau-Léonie Hartmann-Stiftung
                Award ID: None
                Award Recipient :
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2019

                Neurology
                multiple sclerosis,rehabilitation,exercise,high-intensity interval exercise,immune signalling,inflammation,kynurenine pathway,cognition

                Comments

                Comment on this article